Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “UTAH”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 685 records · Page 38Linked to original sources

New Utah program helps curb runaway costs associated with chronic pain.

Take steps to address chronic pain now. Why? Because it's costing the United States 120 billion dollars per year, and much of this expense is due to patients bouncing from clinician to clinician without ever finding relief. Some healthcare organizations and individual practitioners successfully address the problem by taking a multidisciplinary approach to care and equipping patients with strategies to help them take charge.

Chronic Disease↗

Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah.

The frequency of familial dyslipidemia syndromes was determined from blood tests in 33 objectively ascertained families with early coronary heart disease (CHD) (two or more siblings with CHD by the age of 55 years). Three fourths of persons with early CHD in these families had 90th percentile lipid abnormalities (cholesterol level at or above the 90th percentile, triglyceride level at or above the 90th percentile, and/or high-density lipoprotein cholesterol (HDL-C) level at or less than the 10th percentile). The HDL-C and triglyceride abnormalities were twice as common as low-density lipoprotein-cholesterol abnormalities. The most common syndromes found were familial combined hyperlipidemia (36% to 48% of families with CHD), familial dyslipidemic hypertension (21% to 54% of families with CHD), and isolated low levels of HDL-C (15%), with overlapping familial dyslipidemic hypertension with familial combined hyperlipidemia and low-level HDL-C. Well-defined monogenic syndromes were uncommon: familial hypercholesterolemia being 3% and familial type III hyperlipidemia, 3%. Another 15% of families with CHD had no lipid abnormalities at the 90th percentile. Physicians should learn to recognize and treat these common familial syndromes before the onset of CHD by evaluating family history and all three standard blood lipid determinations. Failure to recognize and treat them leaves affected family members at high risk of premature CHD.

Cholesterol, HDL↗

Further linkage data on cystic fibrosis: the Utah Study.

We reported earlier complete linkage between cystic fibrosis and an RFLP of the met proto-oncogene revealed by the probe pmetH. Another clone, pmetD, detects another polymorphism with the TaqI restriction enzyme. Further linkage studies, now involving 22 families, have confirmed the tight linkage of cystic fibrosis to the MET and D7S8 loci. Significant allelic association was found between CF and allelic series defined by the pmetH probe.

Alleles↗

The regionalization of laboratory services at the University of Utah Medical Center. Associated Regional and University Pathologists Inc (ARUP).

We feel that now, four years out, we have achieved the interim goals that we set for ourselves. There are some key aspects that we would do differently if we were now starting over, and we have provided that information to those seeking to begin similar off-site ventures who have sought our advice. There is an interesting constellation of factors that must be present for such an operation to succeed, and the individual components of that constellation will differ by institution and location. The rationale and circumstance will vary profoundly, and what is "right" in one setting may be entirely "wrong" in another. I feel compelled to caution the reader about the myriad of determinants and ingredients that must be considered. Study the precedents and seek knowledgeable advice from financial, legal, insurance, human resource (personnel), and laboratory management professionals. Regional laboratories can succeed. Hospitals may well benefit from a strategy of marketing services to physician staff members and the incremental financial and service benefits from added testing volume can be significant. However, the more expansive the business design, the more complicated the management requirements and demands and, potentially, the higher the risks, costs, pressures, and down-side factors. We feel very strongly about our focus of supporting the pathology and medical technology professions. Our value-added services are geared not only to providing technology, management, and financial services support for our clients, but also to not competing with them for local clientele. We have a program of teaching them how to market to that clientele and of providing the support materials to assist them in so doing. We have progressed from being a hospital laboratory to being a hospital laboratory referral laboratory, and now have also become a referral laboratory for other reference laboratories. As a full-service reference laboratory we send out very few tests, and are continually incorporating new tests and technologies. We have referral testing accounts currently in 42 states and we want to be the very best at what we do, namely, esoteric reference testing. Our credo is that quality at ARUP is making best continually better.

Academic Medical Centers↗